Skip to main content
  • Login
  • Contact
  • Subscribe
  • Advertise With Us

Search form

Home

The Pilot News

Plymouth weather info

  • Home
    • Forms
  • News
    • Local News
    • The Leader of Starke County
    • Culver Citizen
    • Business News
  • Sports
  • Obituaries
  • Classifieds
    • Place an Ad
    • Classified Display Ads
  • Entertainment
    • Calendar
    • Best Of
    • Special Sections
    • Talking About...
    • Games
  • Photos
  • Videos
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Incyte Corp (NQ: INCY)
82.77 USD  +0.35 (+0.42%)
Official Closing Price  /  Updated: 6:23 PM EST, Feb 20, 2020  /  Add to My Watchlist      
View: Quote
Overview
Detailed Quote
Charting
Historical Prices
 News
All News
Press Releases
Related Stories
Blogs
 Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,653,300
Open 82.00
Bid (Size) 79.00 (1)
Ask (Size) 83.79 (5)
Prev. Close 82.42
Today's Range 80.93 - 83.12
52wk Range 71.84 - 96.79
Shares Outstanding 211,969,163
Dividend Yield N/A
Performance
YTD
-3.72%
-3.72%
1 Month
+5.24%
+5.24%
3 Month
-6.37%
-6.37%
6 Month
-3.26%
-3.26%
1 Year
-1.16%
-1.16%
Top News
More News
Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community
February 19, 2020
Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host... Read More
from Business Wire News Releases
Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis
February 19, 2020
Incyte Announces Positive Topline Results from Phase 3 TRuE-AD Program evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis Read More
from Business Wire News Releases
More News
Read More
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
February 13, 2020
from Business Wire News Releases
Incyte to Present at Upcoming Investor Conference
February 11, 2020
from Business Wire News Releases
Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer
February 11, 2020
from Business Wire News Releases
Incyte's Ruxolitinib Works in Patients With Eczema
February 19, 2020
category Market News , INCY
from Motley Fool
Better Buy: Vertex Pharmaceuticals vs. Incyte
February 19, 2020
category CRSP , MPSYF , LLY , and 4 more.
from Motley Fool
Incyte Corp (INCY) Q4 2019 Earnings Call Transcript
February 13, 2020
category Market News , INCY
from Motley Fool
How Incyte Beat Wall Street Estimates in Q4
February 13, 2020
category INCY , LLY , Market News , and 1 more.
from Motley Fool
Incyte's Fourth-Quarter Report Signals Better Times Ahead
February 13, 2020
category NVS , Market News , INCY
from Motley Fool
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
February 12, 2020
category INCY , LLY , Market News
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2019 The Pilot News | 214 N. Michigan | Plymouth, IN 46563 | (574) 936-3101 • 800-933-0356
All property rights for the entire contents of this publication shall be the property of The Pilot News.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media